Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Experimental in-vitro high speed camera analysis of femtosecond laser pattern application

Search Title by author or title

Session Details

Session Title: Moderated Poster Session: FLACS

Session Date/Time: Sunday 11/09/2016 | 14:00-15:00

Paper Time: 14:30

Venue: Poster Village: Pod 1

First Author: : F.Kretz GERMANY

Co Author(s): :    G. Auffarth              

Abstract Details

Purpose:

To evaluate Femtosecond-Laser (Fs) assissted cataract surgery (FLACS) lens fragmentation pattern with the LENSAR Fs-Laser in an in vitro model using a high speed camera.

Setting:

David J. Apple International Laboratory for Ocular Pathology, Department of Ophthalmology, University of Heidelberg, Heidelberg, Germany

Methods:

The LENSAR Femtosecond cataract laser system (LENSAR, LLC) is a combination of a Femtosecond laser with a Scheimpflug-based diagnostic system. We used a special hydrogel based material with high water content with a lens shaped form to visualize Fs-Laser application pattern in the material. A high speed camera (AOS Technologies, Inc.) with a 1.3 M Pixel resolution for 5000 frames per second (fps), 900x700 Pixel resolution for 20.000 fps and 300x320 Pixel resolution for 100.000fps was used.

Results:

Different fragmentation and capsulotomy patterns and energy levels were recorded. With this model the effect of the LENSAR FS-Laser pattern could be visualized and displayed.

Conclusions:

The poster displays results and video-footage of the high speed camera analysis of application pattern of the LENSAR Fs-Laser in a new in vitro model.

Financial Disclosure:

One or more of the authors receives consulting fees, retainer, or contract payments from a competing company, One or more of the authors travel has been funded, fully or partially, by a competing company, One or more of the authors research is funded, fully or partially, by a competing company, One or more of the authors receives non-monetary benefits from a competing company.

Back to previous